O'Shaunessy Ventures Bets $100K on Novel Tick-Bite Prevention Tech
Event summary
- O'Shaunessy Ventures awarded $100K fellowship to Joseph Beyene for tick-bite prevention research
- Beyene's treatment targets unique biological process ticks use to feed on skin
- Field trials and commercial traction efforts planned over next 12 months
- Beyene previously contributed to Vesigen Therapeutics, which raised $28.5M Series A
The big picture
Tick-borne diseases are expanding geographically, creating demand for innovative prevention methods. O'Shaunessy Ventures' $100K bet represents growing investor interest in public health solutions that address emerging biological threats. The fellowship program, launched in 2023, has now backed 19 projects in 2026, demonstrating the firm's commitment to high-risk, high-reward health innovations.
What we're watching
- Commercial Viability
- Whether Beyene can translate lab success to real-world tick prevention
- Market Timing
- The pace at which tick-borne diseases spread into new regions
- Competitive Landscape
- How this novel approach differentiates from existing repellent technologies
Related topics